Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a process that is overseen by the Centers for Medicare and Medicaid Services. He said he would focus on fighting chronic disease,

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.